drugset / Trial / NCT01813474

Investigate the Safety and Tolerability of Olaparib Tablet in Japanese Patients With Advanced Solid Malignancies

NCT01813474

Phase 1 Completed 23 enrolled AstraZeneca
NaSingle-groupOpen-labelTreatment

Summary

The objective of this study will be to investigate the safety and tolerability of olaparib tablet when given orally to Japanese patients with advanced solid malignancies. In addition, the pharmacokinetic profile, MTD (if possible) and efficacy of olaparib will be investigated.

Timeline

Start
2013-03-25
Primary completion
2016-08-31
Completion
2016-08-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Olaparib Small molecule Oral